Consortium IO Logo

CONSORTIUM-IO (NCT04208958) is a first-in-patient clinical trial to evaluate the safety, tolerability and clinical activity of VE800 in combination with Bristol-Myers Squibb's programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo® (nivolumab), as measured by the confirmed overall response rate, in addition to other parameters, in patients with select types of advanced or metastatic cancer.

CONSORTIUM-IO is currently enrolling patients across the U.S. who have been diagnosed with advanced or metastatic melanoma, gastric/gastroesophageal junction adenocarcinoma, or microsatellite-stable colorectal cancer. 

For additional study information or to locate a study site near you, please visit  

If you have questions about the study or are interested in study participation, please email: